3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Tumor Lysis Syndrome
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
14
fludarabine
10
fludarabine phosphate
8
Whole-Body Irradiation
7
thymoglobulin
5
Thiotepa
5
Tacrolimus
5
Stem Cell Transplantation
5
Standard of Care
5
Practice Guidelines as Topic
5
Nivolumab
5
Granulocyte Colony-Stimulating Factor
5
Busulfan
5
Azacitidine
5
venetoclax
4
Radiotherapy
4
Mycophenolic Acid
4
Methotrexate
4
Melphalan
4
Filgrastim
4
Cytarabine
4
Antilymphocyte Serum
4
Rituximab
3
Mesna
3
Leucovorin
3
Dexamethasone
3
Calcium Dobesilate
3
Alemtuzumab
3
ruxolitinib
2
ceritinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hematologic Neoplasms
×
Febuxostat
×
Clear all
NCT03605212
2021-06-03
FLORET
Menarini Group
Phase 1/2
Terminated
30 enrolled
14 charts